“…Thus, inhibition of melanogenesis represents a realistic adjuvant strategy to amplify existing therapeutic approaches ( Figure 1 ) [ 4 , 235 , 367 , 393 ]. In this context, it is worth mentioning that a diverse range of non-toxic inhibitors of tyrosinase activity are available [ 292 , 394 , 395 , 396 ], which in addition to copper chelators (cofactor for tyrosinase) would inhibit tyrosinase and decrease melanin synthesis [ 365 , 367 , 371 , 373 , 397 , 398 , 399 , 400 ]. However, we acknowledge that others, including some of us, have proposed using the melanogenic pathway as a tool for melanoma therapy utilizing the cytotoxicity of melanogenesis products [ 248 , 377 , 380 , 401 , 402 ], also reviewed in [ 4 ].…”